WANY
CATX icon

Wealthspire Advisors (New York)’s Perspective Therapeutics CATX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$138 – 1317
2025
Q3 		$138 Buy
+40
New +$146 ﹤0.01% 2979

Other funds holding CATX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wealthspire Advisors (New York)'s CATX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Perspective Therapeutics (CATX) in Q4 2025, closing a stake of 40 shares — an estimated $138 sold.

Wealthspire Advisors (New York) first reported a position in CATX in Q3 2025 and held it in 1 quarter. The position peaked at $138 in Q3 2025. 117 funds tracked by Wall St. Rank hold CATX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Perspective Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 40 Perspective Therapeutics shares in Q4 2025, an estimated $138.
  • Wealthspire Advisors (New York) first reported a position in Perspective Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Perspective Therapeutics position peaked at $138 in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.